VERSION 3

OCT 23, 2019

OPEN ACCESS

DOI:
[dx.doi.org/10.17504/protocols.io.7k8hkzw](https://doi.org/10.17504/protocols.io.7k8hkzw)

External link:
<https://doi.org/10.1371/journal.pone.0224236>

Protocol Citation: Yueli Zhu, Jiali Pu, Yanxing Chen, Baorong Zhang 2019. Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis. **protocols.io**
<https://dx.doi.org/10.17504/protocols.io.7k8hkzw>

MANUSCRIPT CITATION:
 Zhu Y, Pu J, Chen Y, Zhang B (2019) Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis. PLoS ONE 14(10): e0224236. doi: [10.1371/journal.pone.0224236](https://doi.org/10.1371/journal.pone.0224236)

Decreased risk of Parkinson's disease in diabetic patients with thiazolidinediones therapy: An exploratory meta-analysis V.3

PLOS One

Yueli Zhu¹, Jiali Pu¹, Yanxing Chen¹, Baorong Zhang¹

¹Department of Neurology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou , China

Yueli Zhu

ABSTRACT

Parkinson's disease (PD) is a prevalent and complex neurodegenerative disorder with prominent loss of dopaminergic neurons in the substantia nigra. Rest tremor, rigidity, bradykinesia, and postural instability are the four classical motor symptoms. PD is the second most common neurodegenerative disease. The annual incidence is 14/100 000 of the total population in Europe and the Americas, while the rate increased to 160/100 000 in people aged over 65 years. The incidence is similar in Asia. [Thiazolidinediones](#) (TZDs), [a class of](#) peroxisome proliferator-activated receptor-gamma (PPAR-γ) agonists, can improve insulin sensitivity and lower blood glucose level for patients with type 2 diabetes. Recently, accumulating experiments indicated that TZDs could exert anti-inflammatory and neuroprotective effects in a series of PD animal models. Nevertheless, one randomized controlled trial (RCT) indicated that pioglitazone [is unlikely to be able to](#) slow the disease progression in early PD patients without diabetes. To date, several retrospective observational cohort studies have assessed the association between the TZDs use and the incidence of PD in diabetic patients, but with controversial results. Therefore, we performed this meta-analysis to evaluate the efficacy of TZDs in reducing PD risk among diabetic patients.

ATTACHMENTS

S1 File. Study protocol.doc

License: This is an open access protocol distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

Protocol status: Working

Created: Sep 23, 2019

Last Modified: Oct 23, 2019

PROTOCOL integer ID:
28032

Keywords: Parkinson's disease, incidence, thiazolidinediones, diabetes, meta-analysis